A Single Dose, Placebo-Controlled, Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered by Intravenous Infusion and Subcutaneous Injection.

Trial Profile

A Single Dose, Placebo-Controlled, Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered by Intravenous Infusion and Subcutaneous Injection.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2015

At a glance

  • Drugs Eptinezumab (Primary) ; Eptinezumab (Primary) ; Sumatriptan
  • Indications Migraine
  • Focus Adverse reactions
  • Most Recent Events

    • 15 May 2015 According to an Alder Biopharmaceuticals media release, data from this trial were presented at the 17th Congress of the International Headache Society.
    • 07 May 2015 According to Alder BioPharmaceuticals media release, data from this trial will be presented at 17th Congress of the International Headache Society.
    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top